Earth Science Tech Inc. (ETST) Capitalizing on Diversified, Synergistic Operations to Deliver Dilution-Free and Cash-Flow Driven Growth

• Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine, clinical support, and fulfilment
• RxCompoundStore and Mister Meds are licensed compounding pharmacies, which produce custom medications that are supplied wholesale to independent clinics and directly to consumers through ETST’s other subsidiary, Peaks Curative LLC
• The subsidiaries create a dual-market operation that reduces reliance on one market segment and continues to contribute to Earth Science Tech’s cash-flow-driven and dilution-free growth
• In fiscal year 2026, Earth Science Tech reduced its total liabilities and increased its total assets, resulting in a net increase in shareholder equity

Earth Science Tech (OTC: ETST), a diversified holding company, is building a healthcare platform that vertically integrates various aspects of patient care, from consultation to fulfillment. The company achieves this through the synergy of its specialized subsidiaries RxCompoundStore (“RxCS”), Mister Meds, and Peaks Curative LLC.

RxCS is a Miami-based licensed compounding pharmacy that provides sterile and non-sterile medications. Mister Meds, on the other hand, is an Abilene-based compounding pharmacy that provides sterile medication and handles hazardous drugs. RxCS and Mister Meds compound ingredients, creating custom medications that they then supply wholesale to independent clinics. 

The company’s third subsidiary, Peaks Curative (“Peaks”), targets the B2C segment. Peaks is a telemedicine referral platform that offers asynchronous consultations for compounded medications prepared by RxCS and Mister Meds. Peaks enables patients to explore various treatment options for weight loss, hair growth, and men and women’s sexual health. Additionally, the platform connects patients to licensed medical providers who review duly filled online questionnaires describing the patients’ unique needs before approving medications. Peaks then fulfills the orders, meaning it commercially sells medications directly to consumers. 

By targeting both B2B and B2C segments and integrating digital (telemedicine) and physical manufacturing operations, Earth Science Tech has created a dual-revenue, omnichannel business that has continued to contribute to growth. For instance, the company reported revenues of $35.7 million in the financial year ended March 31, 2026 (“FY2026”), up from $33.1 million in FY2025 and $11.95 million in FY2024 (https://ibn.fm/obdbw).

“In fiscal 2026, we grew revenue, increased earnings, generated positive operating cash flow and strengthened our balance sheet, all without adding debt to our balance sheet,” said Giorgio R. Saumat, CEO and Chairman of the Board (https://ibn.fm/xfmEq).

In addition, according to the FY2026 annual report, Earth Science Tech repaid in full its long-term debt and had no outstanding short-term business loans as of the end of the fiscal year. A review of the balance sheet shows that the company reduced its total liabilities to $1.928 million in FY2026 from $3.146 million in FY2025 and increased its total assets to $8.969 million in FY2026 from $7.066 million in FY2025, reflecting an overall year-over-year increase in shareholder equity (https://ibn.fm/zOV93).

The company believes its current cash flow from operations will be sufficient to fund its anticipated operating and capital requirements for FY2027. And, according to the annual report, it does not anticipate needing to raise additional dilutive financing. This underscores Earth Science Tech’s cash-flow-driven and dilution-free growth. While many OTC companies rely on toxic financing or constant stock dilution to survive, ETST uses organic cash flow and realized asset gains to actively fund its operations, real estate expansions, and share repurchase program. 

As Earth Science Tech continues to seamlessly integrate patient care through its specialized subsidiaries, it is creating a business that is markedly different from other OTC stocks. Not only has the company logged year-over-year growth without saddling itself with debt or relying on toxic financing, but it has also created a dual-market business that does not solely rely on either consumers or businesses. These are hallmarks of a company focused on maximizing shareholder value.

For more information, visit the company’s website at www.EarthScienceTech.com.

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN